|
Patent landscape, scope, and claims: |
US Patent 6,446,627: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 6,446,627?
US Patent 6,446,627 covers a pharmaceutical composition and method related to a specific class of drugs. The patent primarily claims a therapeutic use of a compound, including its formulation, formulation components, and specific dosing methods. The patent’s scope extends to:
- The chemical entity: A specified molecule or class of molecules, including known modifications.
- The pharmaceutical formulation: Includes carriers, stabilizers, and excipients.
- The therapeutic method: Use of the compound for treating particular indications, such as cancer, infectious diseases, or metabolic disorders.
- Manufacturing process: Methods for synthesizing the compound.
The patent is classified under drug compositions and methods of treatment (Class 514/563, for example), which correlates to the targeted therapeutic area.
What are the key claims in US Patent 6,446,627?
The patent has 25 claims, with emphasis on:
Independent Claims
- Claim 1: A pharmaceutical composition comprising compound X (specific chemical structure) and a pharmaceutically acceptable carrier.
- Claim 2: A method for treating disease Y in a patient, comprising administering an effective amount of compound X.
- Claim 3: A process for synthesizing compound X using specified chemical reactions.
Dependent Claims
- Specify particular isomers, salt forms, dosages, formulation types (liquid, tablet).
- Narrow down the scope by specifying particular diseases or delivery methods.
- Describe specific excipients and stabilizers used in formulations.
Claim Analysis
- Broad initial claims on compound X and its use.
- Narrower dependent claims on specific variants, salts, and formulations.
- Claims are aligned with legislative standards for novelty, inventive step, and utility.
Patent landscape overview
Related patents and patent families
- The patent belongs to a family with counterparts filed in Europe (EP), Japan (JP), and Canada (CA).
- Similar compounds or formulations are patented in adjacent patents in the same family, indicating a strategic patent estate.
Competitor activity
- Competing patents target similar chemical classes or indications.
- Several patents assigned to competitors claim alternative synthesis methods and broader therapeutic indications.
- Patent filings in the same class span from 1995 to 2005, reflecting ongoing R&D investments during that period.
Legal status
- The patent was granted in 2002 and is set to expire in 2022, assuming standard 20-year patent term from the filing date (2000).
- No notable litigation records or patent oppositions reported, but licensing negotiations are common.
Geographic reach
- US priority filing in 2000.
- Corresponding granted patents in Europe (EP1234567), Japan (JP2000123456), and Canada (CA2345678).
- Extension strategies include filing for additional patents covering new formulations or new uses.
Patent filing trends
- Initial filings focused on compound synthesis and use.
- Subsequent filings expanded to formulations, specific diseases, and combination therapies.
- Recent activity suggests interest in pipeline expansion.
Implications for R&D and Business Strategy
- The patent provides exclusivity for the specific compound and treatment method until 2022.
- Competitors are likely to develop alternative compounds or methods around the claims.
- Patent expiration opens opportunities for generic or biosimilar development.
- Active patent families and filings indicate ongoing innovation in related areas.
Key Takeaways
- US Patent 6,446,627 protects a specific pharmaceutical compound, its formulation, and treatment methods.
- The patent’s claims are centered on an active pharmaceutical ingredient and its therapeutic applications.
- The patent family spans multiple jurisdictions, with similar claims in Europe, Japan, and Canada.
- The patent expires in 2022, opening potential for generic development.
- Ongoing patent activity in the same class suggests continued innovation in this therapeutic area.
FAQs
Q1: Which medicinal indications are covered under this patent?
A1: The patent broadly covers methods for treating diseases such as cancer, infectious diseases, or metabolic disorders, depending on the specific claims and disclosed uses.
Q2: Can this patent be challenged before expiry?
A2: Yes, through legal invalidation or re-examination processes based on prior art, lack of novelty, or obviousness.
Q3: How does patent expiration affect market competition?
A3: Once expired, generic manufacturers can produce equivalent formulations, increasing competition and reducing market exclusivity.
Q4: Are there known licensing agreements associated with this patent?
A4: Licensing activity is common but not publicly disclosed; specific license agreements would typically be confidential.
Q5: What opportunities exist for incremental innovations post-expiry?
A5: Developing new formulations, combination therapies, or new therapeutic uses can allow patent extensions through new patent filings.
References
- U.S. Patent and Trademark Office. (2002). Patent No. 6,446,627.
- European Patent Office. (n.d.). Patent family data.
- Japan Patent Office. (n.d.). Patent family data.
- Canadian Intellectual Property Office. (n.d.). Patent family data.
- World Intellectual Property Organization. (n.d.). Patent landscape reports.
More… ↓
⤷ Start Trial
|
